How AI Is Transforming Medicinal Chemistry Between Discovery and Manufacture
In medicinal chemistry, the “make” stage of the design–make–test–analyze (DMTA) cycle is often where good ideas go to die. Synthetic …
Biopharma Insights
"AI Scientists" - New Collaborators for Rare Disease Research?
In the quest to understand and treat the over 6,000 rare diseases, researchers encounter a number of limitations – in …
What are Foundation Models in Biology and Healthcare?
Content: History of AI in the Context of Foundation Models The Technology Stack Behind Foundation Models The Paradigm Shift in …
The Pivotal Role of AI in Clinical Trials: From Digital Twins to Synthetic Control Arms
Artificial Intelligence (AI) is redefining the clinical trial process, offering solutions that address long-standing challenges in drug development. The traditional …
Building AI Solutions for Life Sciences and Healthcare
Artificial intelligence (AI) has swiftly become a focal point in modern industry discussions. Organizations are transitioning from mere experimentation to …
Into the Unknown — How Artificial Intelligence Can Help Biotech Companies Chart the Dark Genome
With DeepMind’s release of AlphaGenome—a deep learning model that can predict the relevance of variants in both coding and non-coding …
Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond
In this report: Intro: The New Framework “AI Drug Discovery” is About Holism "AI Drug Discovery" is About Building Software …
AI-Based Next-Generation-Phenotyping for Rare Disease Diagnosis
Rare diseases, which affect more than 300 million people worldwide, are often difficult to diagnose. Many patients wait five years …
How AI, Graphs, and GraphRAG Are Set to Revolutionize Alzheimer's Gene Research and Treatment
An estimated 6.9 million Americans aged 65 and older are living with Alzheimer’s. Without major medical breakthroughs, that number is …
Novotech Report: Over 800 Global IPF Trials Since 2020, Led by Asia-Pacific
Novotech CRO has released a global market analysis focused on the clinical trial landscape for Idiopathic Pulmonary Fibrosis (IPF), identifying …
Report: Nearly 80% of Life Sciences Leaders Considering Virtual Models for Observational Research
A new industry report from PicnicHealth reveals that nearly 80% of life sciences leaders are open to using virtual models …
AI in Drug Safety: From Concept to Reality, The Industry's Path Forward
Pharmaceutical companies are dealing with an unprecedented volume of safety data with artificial intelligence moving from theoretical applications to practical …